Pages that link to "Q64922700"
Jump to navigation
Jump to search
The following pages link to Ticarcillin-tobramycin-rifampin: in vitro synergy of the triplet combination against Pseudomonas aeruginosa. (Q64922700):
Displaying 7 items.
- Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa (Q24612271) (← links)
- Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis (Q33975978) (← links)
- Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: prospective trial using the Zelen protocol (Q35867214) (← links)
- Antimicrobial agent therapy for Pseudomonas aeruginosa (Q36756391) (← links)
- The role of carbapenems in initial therapy for serious Gram-negative infections (Q37169849) (← links)
- Rifampin combination therapy for nonmycobacterial infections (Q37672039) (← links)
- Addition of rifampin to carboxypenicillin-aminoglycoside combination for the treatment of Pseudomonas aeruginosa infection: clinical experience with four patients (Q39849123) (← links)